Darnatein is a biotechnology company founded in 2012, based in South Korea.  We operate as a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), with a focus on developing design‑augmented biologics using synthetic biology, protein engineering and RNA modalities to address degenerative diseases, especially in the musculoskeletal system.

Darnatein uses design-augmented AI to develop novel protein chimeras with superior efficacy compared to original naturally occurring parent ligands. The current focus is on developing improved bone morphogenic proteins (BMPs), which are critical to bone and cartilage healing. Darnatein design augmented-BMPs are engineered for enhanced therapeutic potency, reducing required doses and minimizing the likelihood of adverse events. Our most advanced assets are DRT-101 and DRT-102. 

DRT-101 is a Chimeric Activin A/BMP7 protein with over 30x higher activity compared to natural BMP7. Current preclinical data indicate DRT-101 potential as a first-in-class disease-modifying osteoarthritis drug (DMOAD).

DRT-102 is a clinical-stage asset for spinal fusion. In an exploratory first-in-human clinical trial, DRT-102 demonstrated potential efficacy compared to placebo (75% bone fusion rate) with an excellent safety profile. DRT-102 is expected to be used as a reinforcing agent for spinal fusion and implant procedures for disc patients.